MA51999B1 - Nouvelle formulation pharmaceutique comprenant deux antagonistes recepteurs de nk-1/nk-3. - Google Patents

Nouvelle formulation pharmaceutique comprenant deux antagonistes recepteurs de nk-1/nk-3.

Info

Publication number
MA51999B1
MA51999B1 MA51999A MA51999A MA51999B1 MA 51999 B1 MA51999 B1 MA 51999B1 MA 51999 A MA51999 A MA 51999A MA 51999 A MA51999 A MA 51999A MA 51999 B1 MA51999 B1 MA 51999B1
Authority
MA
Morocco
Prior art keywords
new pharmaceutical
pharmaceutical formulation
receptor antagonists
hexahydropyrazino
dimethylpropanamide
Prior art date
Application number
MA51999A
Other languages
English (en)
Other versions
MA51999A (fr
Inventor
Mike Trower
Mary Kerr
David Elder
Monica Lazaro
Derek Bush
Original Assignee
Kandy Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kandy Therapeutics Ltd filed Critical Kandy Therapeutics Ltd
Publication of MA51999A publication Critical patent/MA51999A/fr
Publication of MA51999B1 publication Critical patent/MA51999B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne d'une manière générale de nouvelles formulations pharmaceutiques contenant le 2- [3,5-bis(trifluorométhyl)phényl]-n-{4-(4-fluoro-2-méthylphényl)-6-[(75,9a5)-7-(hydroxyméthyl)hexahydropyrazino[2,1-c] [1,4]oxazin-8(1h)-yl]-3-pyridinyl}-n2-diméthylpropanamide, leurs procédés de préparation et leur utilisation en thérapie médicale.
MA51999A 2018-03-14 2019-03-13 Nouvelle formulation pharmaceutique comprenant deux antagonistes recepteurs de nk-1/nk-3. MA51999B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862642622P 2018-03-14 2018-03-14
PCT/EP2019/056303 WO2019175253A1 (fr) 2018-03-14 2019-03-13 Nouvelle formulation pharmaceutique comprenant des antagonistes doubles des récepteurs nk-1/nk-3

Publications (2)

Publication Number Publication Date
MA51999A MA51999A (fr) 2021-01-20
MA51999B1 true MA51999B1 (fr) 2024-02-29

Family

ID=65817992

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51999A MA51999B1 (fr) 2018-03-14 2019-03-13 Nouvelle formulation pharmaceutique comprenant deux antagonistes recepteurs de nk-1/nk-3.

Country Status (31)

Country Link
US (5) US10774091B2 (fr)
EP (1) EP3765024B1 (fr)
JP (1) JP7433252B2 (fr)
KR (1) KR20200139138A (fr)
CN (1) CN112292132A (fr)
AU (1) AU2019233606A1 (fr)
BR (1) BR112020017388A2 (fr)
CA (1) CA3092238A1 (fr)
CL (1) CL2020002350A1 (fr)
CO (1) CO2020011262A2 (fr)
CR (1) CR20200385A (fr)
DK (1) DK3765024T3 (fr)
EA (1) EA202092131A1 (fr)
EC (1) ECSP20057488A (fr)
ES (1) ES2974300T3 (fr)
FI (1) FI3765024T3 (fr)
GE (1) GEP20237503B (fr)
HR (1) HRP20240120T1 (fr)
HU (1) HUE065300T2 (fr)
IL (1) IL276959B1 (fr)
JO (1) JOP20200227A1 (fr)
LT (1) LT3765024T (fr)
MA (1) MA51999B1 (fr)
MX (2) MX2020009438A (fr)
PE (1) PE20210395A1 (fr)
PH (1) PH12020551457A1 (fr)
PT (1) PT3765024T (fr)
RS (1) RS65257B1 (fr)
SG (1) SG11202008226YA (fr)
SI (1) SI3765024T1 (fr)
WO (1) WO2019175253A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10906874B2 (en) 2016-09-18 2021-02-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. YAP1 inhibitors that target the interaction of YAP1 with OCT4
PT3765024T (pt) 2018-03-14 2024-02-19 Kandy Therapeutics Ltd Formulação farmacêutica inovadora que compreende antagonistas duplos dos recetores nk-1/nk-3
AU2019236196A1 (en) 2018-03-14 2020-10-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. YAP1 inhibitors that target the interaction of YAP1 with Oct4
KR20220101090A (ko) 2019-11-15 2022-07-19 칸디 테라퓨틱스 리미티드 Nt-814의 핵심 중간체인 6-클로로-4-(4-플루오로-2-메틸페닐)피리딘-3-아민의 새로운 화학적 제조 방법
KR102484687B1 (ko) * 2022-03-04 2023-01-05 (주)씨앤엘디 페노피브레이트를 포함하는 이상지질혈증의 예방 또는 치료용 약학 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3097618A (en) 1960-12-01 1963-07-16 Raymond Bag Corp Manufacture of multi-wall bag having heat-sealed liner
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
GB9907571D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Compounds
EP1299100B1 (fr) 2000-06-12 2007-07-25 The University Of Rochester Methode de traitement de bouffees de chaleur, au moyen d'un antagoniste du recepteur de la tachykinine
EP1192952A3 (fr) 2000-09-28 2003-03-26 Pfizer Products Inc. Composition pour le traitement de la dépression et de l'anxieté contenant un antagoniste du recepteur NK-3 et un antagoniste du récepteur NK-1
WO2002089802A2 (fr) 2001-05-08 2002-11-14 Schering Corporation Utilisation d'antagonistes de recepteur de neurokinine pour le traitement de maladies liees aux androgenes
CA2509090C (fr) 2002-12-23 2012-01-24 Janssen Pharmaceutica N.V. Derives de 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane substitues et leur utilisation en tant qu'antagonistes des neurokinines
JO2696B1 (en) 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
US7525659B2 (en) 2003-01-15 2009-04-28 Negevtech Ltd. System for detection of water defects
EP1643998B1 (fr) 2003-07-03 2007-08-29 F. Hoffmann-La Roche Ag Antagonistes doubles des recepteurs nk1/nk3 pour traiter la schizophrenie
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
JO2525B1 (en) 2004-04-08 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin
CA2565953A1 (fr) 2004-05-12 2005-11-24 Pfizer Products Inc. Derives de piperidine en tant qu'antagonistes de nk1 et nk3
DE102004033902A1 (de) 2004-07-14 2006-02-16 Zentaris Gmbh Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's)
WO2006013205A1 (fr) 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Antagonistes des récepteurs de la neurokinine-1 pour le traitement des états sensibles à une élévation de la testostérone
US20060030600A1 (en) 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
KR101292348B1 (ko) * 2005-09-09 2013-09-09 네르 쎄라퓨틱스 리미티드 피리딘 유도체 및 그의 정신병적 장애의 치료에 있어서의용도
AU2008240804B2 (en) 2007-04-20 2013-02-21 F. Hoffmann-La Roche Ag Pyrrolidine derivatives as dual NK1/NK3 receptor antagonists
GB0814340D0 (en) 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
AU2010288502B2 (en) * 2009-08-27 2013-12-12 KaNDy Therapeutics Ltd. Anhydrate forms of a pyridine derivative
US8487102B2 (en) 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
ES2376564B1 (es) 2010-08-12 2013-01-24 Manuel Vicente Salinas Martín Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer.
GB2488788B (en) * 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
WO2013082388A1 (fr) 2011-12-02 2013-06-06 Glaxosmithkline Intellectual Property (No. 2) Limited Inhibiteurs de peptide déformylase
KR101739820B1 (ko) 2012-03-28 2017-05-25 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 비수성 액체 형태의 경구투여용 약학 조성물
US20150272927A1 (en) 2012-12-03 2015-10-01 University Of Washington Through Its Center For Commercialization Methods and compositions for treating vasomotor symptoms
GB201315846D0 (en) 2013-09-05 2013-10-23 Imp Innovations Ltd Method for treating or preventing hot flushes
ES2753539T3 (es) * 2015-05-18 2020-04-13 Nerre Therapeutics Ltd Antagonista del receptor NK-1/NK-3 para el tratamiento de los sofocos
PT3765024T (pt) 2018-03-14 2024-02-19 Kandy Therapeutics Ltd Formulação farmacêutica inovadora que compreende antagonistas duplos dos recetores nk-1/nk-3
KR20220101090A (ko) 2019-11-15 2022-07-19 칸디 테라퓨틱스 리미티드 Nt-814의 핵심 중간체인 6-클로로-4-(4-플루오로-2-메틸페닐)피리딘-3-아민의 새로운 화학적 제조 방법

Also Published As

Publication number Publication date
SG11202008226YA (en) 2020-09-29
SI3765024T1 (sl) 2024-05-31
US20200361956A1 (en) 2020-11-19
BR112020017388A2 (pt) 2020-12-15
CO2020011262A2 (es) 2020-12-10
CR20200385A (es) 2021-05-21
KR20200139138A (ko) 2020-12-11
US20230382922A1 (en) 2023-11-30
JP2021517590A (ja) 2021-07-26
CN112292132A (zh) 2021-01-29
PE20210395A1 (es) 2021-03-02
US20190284205A1 (en) 2019-09-19
IL276959B1 (en) 2024-03-01
PT3765024T (pt) 2024-02-19
US20200361957A1 (en) 2020-11-19
FI3765024T3 (fi) 2024-02-14
WO2019175253A1 (fr) 2019-09-19
CL2020002350A1 (es) 2021-04-16
JOP20200227A1 (ar) 2020-09-13
EP3765024B1 (fr) 2023-11-22
GEP20237503B (en) 2023-04-25
PH12020551457A1 (en) 2021-11-22
US11591346B2 (en) 2023-02-28
AU2019233606A1 (en) 2020-09-17
US10774091B2 (en) 2020-09-15
DK3765024T3 (da) 2024-02-12
ECSP20057488A (es) 2020-12-31
US11767328B2 (en) 2023-09-26
HUE065300T2 (hu) 2024-05-28
EA202092131A1 (ru) 2020-11-27
MA51999A (fr) 2021-01-20
IL276959A (en) 2020-10-29
US11787820B2 (en) 2023-10-17
US20230174552A1 (en) 2023-06-08
EP3765024A1 (fr) 2021-01-20
MX2020009438A (es) 2022-05-11
LT3765024T (lt) 2024-02-26
MX2022005706A (es) 2022-06-08
JP7433252B2 (ja) 2024-02-19
ES2974300T3 (es) 2024-06-26
RS65257B1 (sr) 2024-03-29
HRP20240120T1 (hr) 2024-04-12
CA3092238A1 (fr) 2019-09-19

Similar Documents

Publication Publication Date Title
MA51999B1 (fr) Nouvelle formulation pharmaceutique comprenant deux antagonistes recepteurs de nk-1/nk-3.
EA201391468A1 (ru) 1,3-оксазины в качестве ингибиторов bace1 и/или bace2
US10130629B2 (en) Pharmaceutical combinations
Piepers et al. Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial
MA40893B1 (fr) Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
MA39092A1 (fr) Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides
MA38183A1 (fr) Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
MA41434B1 (fr) 7-benzyl-4-(4-(trifluorométhyl)benzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4h)-one, ses sels et leur utilisation en thérapie
MA47447B1 (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
EA201391670A1 (ru) 1,3-оксазины в качестве ингибиторов bace1 и/или bace2
SV2005002148A (es) "compuestos moduladores de la actividad c-kit y usos de los mismos"
MA33509B1 (fr) Dérivés de l'oxazine et leur utilisation dans le traitement de troubles neurologiques
DK1499607T3 (da) 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-quinoliner som urotensin II-receptorantagonister
MA38347A1 (fr) Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak)
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
WO2014022116A8 (fr) Composés de pyrazolone substituée et leurs procédés d'utilisation
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
MA35748B1 (fr) Fluorométhyl-5,6-dihydro-4h-[1,3]oxazines
MA40875A (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
PH12020551891A1 (en) New quinoline derivatives
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
MA39294A1 (fr) Polythérapie contre le cancer
MA38358B1 (fr) Formulations de composés organiques
MX2021008295A (es) Formas sólidas que comprenden (s)-4-(4-(4-(((2-(2,6-dioxopiperidin -3-il)-1-oxoisoindolin-4-il)oxi)metil)bencil)piperazin-1-il)-3-fl uorobenzonitrilo y sales del mismo, composiciones que comprenden y métodos de utilización del mismo.